Search 

Our goal is to advance the development of analytical technologies by combining our specialist knowledge from chemistry, biology, physics and computer science and the transfer of our results to science, business and the public are our main goals.

maintect GmbH was founded 2018 in collaboration with Mainz University Medical Center Germany by ophthalmological scientists.
maintect is developing an innovative antibody treatment for a new target instead of the well-known VEGF in wAMD (wet age-related-macular-degeneration, one of the most frequent causes of blindness). This new antibody will help the patients who don’t benefit from anti-VEGF treatment and all others. maintect applied already for patent in several countries. Combination with anti-VEGF is also an option. In parallel, the company is developing a companion diagnostic kit using lateral flow assays for anti-VEGF treatment in wAMD. This test will determine which patients will benefit most from the new treatment and will facilitate the market entrance. Furthermore, the company is interested in contract research and collaborations in building diagnostic kits.

The founder team of PreOmics started working on optimized LC-MS proteomic workflows at the Matthias Mann lab in 2010. After establishing an optimized and easier sample preparation process in 2014, Dr. Nils A. Kulak together with Dr. Garwin Pichler set forth to validate their technologies with external laboratories and researchers. With a lot of support of proteomics experts, engineers and industry designers, they made their first product ready-for-market. The PreOmics team won several awards for their business idea, were supported by various accelerator programs and established their company in the beginning of 2016. They are now located at the IZB in Martinsried just south of Munich.
We empower our clients in life science to establish biological knowledge through efficient reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy and commitment empower us to be creative and quality focused. A trusted partner with deeply rooted scientific experience.

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!